Orphan Dominance and Oral Semaglutide Market Shifts

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: CHMP's rare disease approval concentration hitting 42%, oral semaglutide's market implications, and JCA capacity constraints becoming reality. Let's get into it.

SaraThe May CHMP session tells a story about where European drug development is heading. Eight approvals including nerandomilast for IPF and camizestrant for ESR1-mutated breast cancer. But the pattern matters more than individual products.

MarcusExactly. EMA data shows 16 orphan-designated products out of 38 new active substances in 2025 - that's 42% orphan designation rate. The May session reinforces this trend toward rare, molecularly targeted indications. From a HEOR perspective, this fundamentally changes evidence requirements.

SaraI'm not convinced this trend is sustainable from a market access standpoint. Yes, orphan designations get regulatory advantages, but they still face HTA scrutiny. When 42% of your pipeline depends on small patient populations and premium pricing, you're creating a coverage crisis.

MarcusBut that's exactly why the evidence has to be bulletproof. These aren't lifestyle drugs - IPF kills within years, ESR1-mutated breast cancer has limited options. The clinical need is undeniable, and the regulatory pathway reflects that reality.

SaraClinical need doesn't automatically translate to affordable access. We're seeing innovation concentrated in areas where traditional RCT designs barely work and economic models depend on massive extrapolation. That's a recipe for HTA rejection, orphan status or not.

MarcusThe CHMP approved oral semaglutide for weight management - the first oral GLP-1 for this indication. This isn't incremental; it's removing the injection barrier that's kept millions from accessing GLP-1 therapy.

SaraI disagree completely. Oral semaglutide is market expansion masquerading as innovation. Novo already dominates GLP-1 with Wegovy injections. Now they get a second bite with oral formulation, extending patents and market exclusivity. Where's the clinical advance?

MarcusPatient preference isn't trivial. Injection avoidance is a real barrier to adherence. If oral delivery improves persistence rates, that's genuine clinical value, not just commercial strategy.

SaraShow me the head-to-head persistence data. Without comparative effectiveness evidence, this looks like lifecycle management. HTA bodies won't pay premium prices for formulation changes without proven superiority.

MarcusFair point on the evidence gap. But the regulatory approval suggests EMA saw sufficient differentiation. The question is whether payers will agree when this hits HTA review.

SaraThe EMA's Emergency Task Force is now collaborating with African Medicines Agency on Ebola outbreak response. This is the first major public health emergency where EMA works directly with AMA since it became operational.

MarcusPromising for global regulatory alignment, but I'm skeptical about practical impact. Emergency collaboration sounds good politically, but does it actually accelerate access to treatments in outbreak settings? The track record on emergency use authorizations suggests bureaucracy doesn't disappear during crises.

SaraYou're missing the strategic significance. This establishes precedent for coordinated regulatory responses beyond Europe. When the next pandemic hits, having established collaboration frameworks with African regulators could be crucial.

MarcusMaybe. But emergency collaboration needs to prove it can deliver faster approvals, not just better meetings. The real test is whether African patients get access to treatments weeks or months earlier because of this coordination.

SaraThe HTA Coordination Group estimates 17 JCAs for cancer medicines and 8 for ATMPs in 2025. Given what we're seeing with orphan designation rates, those numbers look conservative.

MarcusCompletely agree. If 42% of approvals carry orphan designation and most target oncology or rare diseases, the JCA system is about to face a capacity crunch. These assessments require deeper clinical expertise than standard indications.

SaraThe resource constraint is real, but I think the bigger issue is methodology. JCA frameworks weren't designed for ultra-rare diseases with single-arm trials and synthetic control arms. We're forcing orphan drugs through a process built for conventional evidence.

MarcusThat's exactly why these early JCAs matter so much. They're establishing precedents for how European HTA handles innovative trial designs. Get it wrong now, and you create barriers for legitimate innovation.

SaraOr you create loopholes that companies exploit to avoid generating proper evidence. The orphan pathway already reduces evidence requirements. Adding JCA flexibility on top risks undermining the entire evidence standard.

MarcusThe evidence integration challenge is accelerating. Multiple study designs - pragmatic trials, external control arms, observational studies - are becoming standard for decision-making beyond traditional RCTs.

SaraWhich brings us back to the fundamental question: are we adapting evidence standards to reality, or lowering the bar because companies can't meet traditional requirements? The CHMP's May session suggests European regulators are comfortable with this evolution. Whether payers follow remains the critical unknown.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.